Amphastar Pharmaceuticals Inc logo

AMPH - Amphastar Pharmaceuticals Inc News Story

$19.97 0.4  2.1%

Last Trade - 14/05/21

Mid Cap
Market Cap £663.2m
Enterprise Value £645.2m
Revenue £262.0m
Position in Universe 2882nd / 6849

Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

Tue 6th April, 2021 9:05pm
For best results when printing this announcement, please click on link below:

RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar
Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO,
Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P
Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive
V.P. Corporate Administration Center and Sales & Marketing, will participate
in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare
Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time.

This presentation will be made available webcast and may be accessed by
visiting Amphastar’s Pharmaceuticals website at
This webcast will be available for 90 days following the presentation.

About Amphastar:

Amphastar is a specialty pharmaceutical company that focuses primarily on
developing, manufacturing, marketing, and selling technically-challenging
generic and proprietary injectable, inhalation, and intranasal products.
Additionally, the Company sells insulin active pharmaceutical ingredient
products. Most of the Company’s finished products are used in hospital or
urgent care clinical settings and are primarily contracted and distributed
through group purchasing organizations and drug wholesalers. More information
is available at the Company’s website at

The Amphastar Pharmaceuticals’ logo and other trademarks or service marks of
Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene(®),
Amphadase(®) and Cortrosyn(®), are the property of Amphastar
Pharmaceuticals, Inc.

Forward Looking Statements

All statements in this press release that are not historical are
forward-looking statements. These statements are not historical facts but
rather are based on Amphastar’s historical performance and its current
expectations, estimates, and projections regarding Amphastar’s business,
operations, and other similar or related factors. Words such as “may,”
“might,” “will,” “could,” “would,” “should,”
“anticipate,” “predict,” “potential,” “continue,”
“expect,” “intend,” “plan,” “project,” “believe,”
“estimate,” and other similar or related expressions are used to identify
these forward-looking statements, although not all forward-looking statements
contain these words. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks, uncertainties, and
assumptions that are difficult or impossible to predict and, in some cases,
beyond Amphastar’s control. Actual results may differ materially from those
in the forward-looking statements as a result of a number of factors,
including those described in Amphastar’s filings with the Securities and
Exchange Commission, including in the Annual Report on Form 10-K for the year
ended December 31, 2020, filed with the SEC on March 15, 2021. You can locate
these reports through the Company’s website at and
on the SEC’s website at The forward-looking statements in this
release speak only as of the date of the release. Amphastar undertakes no
obligation to revise or update information or any forward-looking statements
in this press release to reflect events or circumstances in the future, even
if new information becomes available or if subsequent events cause
Amphastar’s expectations to change.

 Bill Peters Chief Financial Officer (909) 476-3416  

GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.